Introduction
Biotechnology involves the application of biological systems, organisms and processes to develop products and technologies. Advances in genomics, genetic engineering, synthetic biology and biopharmaceuticals offer transformative opportunities for India. However, their application requires robust regulatory oversight to balance innovation with public health, environmental protection and ethical considerations.
Opportunities offered by biotechnology
- Healthcare and disease management: Genomics, molecular diagnostics and biotechnology-based medicines enable early diagnosis, targeted treatment and improved disease management.
Example: Indigenous development of vaccines such as Covaxin demonstrated India’s capacity for biotechnology-led public health innovation. - Affordable biopharmaceuticals: Biotechnology strengthens domestic production of vaccines, biosimilars, recombinant medicines and therapeutic products.
Example: India’s biosimilar industry improves access to complex biological medicines at relatively affordable costs. - Agricultural productivity: Genetic engineering and molecular breeding can improve crop yields, nutritional quality and resistance to pests and climatic stresses.
Example: Bt cotton incorporates insect resistance, reducing losses from bollworm infestations. - Climate-resilient agriculture: Biotechnology can contribute to the development of crops tolerant to drought, salinity and extreme temperatures.
Example: Genome-editing techniques offer possibilities for developing climate-resilient crop varieties. - Industrial applications: Industrial biotechnology enables the production of biofuels, bio-based chemicals, enzymes and biodegradable materials, reducing dependence on fossil-based inputs.
Initiative: The BioE3 Policy promotes biotechnology-driven manufacturing for a sustainable and circular bioeconomy. - Environmental sustainability: Bioremediation and microbial technologies can help treat polluted water, degrade contaminants and manage organic waste.
Example: Microorganisms can be used to treat industrial effluents and contaminated sites.
Concerns and challenges
- Biosafety risks: Genetically modified organisms may have unintended effects on human health, biodiversity and ecological balance if inadequately assessed.
Example: Concerns surrounding gene flow from genetically modified crops to related wild varieties. - Biosecurity threats: Advances in synthetic biology and genetic engineering could be misused to develop biological weapons or enhance the harmful properties of pathogens.
Framework: Biological Weapons Convention (1972) prohibits the development, production and stockpiling of biological and toxin weapons. - Ethical concerns: Human genome editing, embryo research and genetic interventions raise questions concerning consent, human dignity and the possibility of designer babies.
Example: The controversy surrounding germline genome editing demonstrates the risks of unregulated experimentation. - Genetic privacy: Genomic databases contain sensitive personal information that could be misused for discrimination, profiling or unauthorised commercial purposes.
Concern: Genetic information may reveal predispositions to diseases, affecting individual privacy and autonomy. - Socio-economic inequalities: High costs of advanced therapies and unequal access to biotechnology may widen healthcare and agricultural inequalities.
Example: Small farmers may face dependence on proprietary seeds and technologies. - Regulatory and institutional capacity: Rapid technological developments can outpace existing regulatory frameworks, scientific expertise and monitoring mechanisms.
Example: Assessing the long-term ecological consequences of genome-edited organisms requires specialised scientific capacity.
Measures for responsible biotechnology development
- Strengthen regulatory oversight: Ensure transparent, science-based risk assessment and monitoring of genetically modified organisms and emerging biotechnologies.
Institution: Genetic Engineering Appraisal Committee (GEAC) evaluates proposals involving the environmental release of genetically engineered organisms. - Promote ethical research: Establish institutional ethics committees, informed-consent procedures and safeguards against unethical human experimentation.
Framework: ICMR’s National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. - Enhance biosecurity preparedness: Strengthen laboratory safety, pathogen surveillance, reporting mechanisms and controls against misuse of biological research.
Framework: National Biosafety Guidelines provide safeguards for research involving genetically engineered organisms. - Invest in indigenous research: Expand public funding, research infrastructure and industry-academia collaboration to reduce dependence on imported technologies.
Initiative: BioE3 Policy seeks to promote high-performance biomanufacturing in India. - Ensure equitable access: Encourage affordable biotechnology-based medicines, public-sector research and technology transfer to prevent monopolisation.
Example: India’s generic pharmaceutical and vaccine manufacturing capabilities demonstrate the potential of affordable biotechnology.
Conclusion
Biotechnology can become a major driver of India’s healthcare transformation, agricultural resilience and industrial competitiveness. However, its benefits must be accompanied by precautionary regulation, ethical safeguards, biosecurity preparedness and equitable access. India needs an innovation ecosystem that is scientifically advanced, socially responsible and environmentally sustainable.